Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.

10542Background: Poly (ADP-ribose) Polymerase inhibitors (PARPi) target tumors with deficiencies in DNA repair mechanisms. Talazoparib (TAL), a potent PARP inhibitor, demonstrated significant effic...